Merck Emend Coverage Decision Will Not Affect Aloxi, MGI Says
This article was originally published in The Pink Sheet Daily
Executive Summary
The Centers for Medicare & Medicaid Services' initiation of a national coverage determination process for Merck' anti-emetic Emend will have no impact on MGI Pharma's Aloxi, MGI CEO Lonnie Moulder said during a July 14 conference call
You may also be interested in...
Merck Emend Medicare National Coverage Decision Expected By April 2005
CMS is accepting public comment on whether aprepitant is a “full replacement” for other anti-emetic treatments in response to an “internally generated” coverage determination request.
Medicare Reaffirms Faith In Formulary Review Process Ahead Of Part D Changes
Dramatic transformation in the US Medicare Part D benefit design does not require any changes to CMS’ overall approach to reviewing formulary submissions from private drug plan sponsors, the agency says in its final guidance implementing the design changes for 2025.
Cost-Based Pricing: The Real Threat Hiding In Latest US Drug Price Headlines
Bernie Sanders is back at it, getting headlines for demanding immediate price cuts to Novo’s blockbuster GLP-1 brands. But behind the familiar rhetoric is a newer threat: academic research on cost-based pricing that could one day feed into the emerging Medicare ‘negotiation’ system.